<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03328832</url>
  </required_header>
  <id_info>
    <org_study_id>201601271A0</org_study_id>
    <nct_id>NCT03328832</nct_id>
  </id_info>
  <brief_title>Combined Topical Tranexamic Acid With Floseal® in Total Knee Arthroplasty</brief_title>
  <official_title>Comparison of Combined Topical Tranexamic Acid With Floseal® With Intravenous Tranexamic Acid on Blood Loss in Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our purpose of this study therefore is to conduct a prospective randomized controlled trial
      to investigate the blood-conservation effect of combined topical application of these two
      hemostatic agents in different time during surgery and the safety compared with single
      topical application of TKA in a primary TKA procedure
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total knee arthroplasty (TKA) is associated with considerable blood loss and increasing needs
      for allogenic blood transfusion. Tranexamic acid (TXA), an inhibitor of fibrinolysis, was
      reportedly effective reducing blood loss after standard TKA. Our previous experiences in
      minimally invasive (MIS) TKA showed that intraoperative infusion of TXA reduced 45% of
      postoperative blood loss and needs for transfusion from 20% to 4%. There were some reports
      demonstrating the cost-effectiveness of topical application of TXA in TKA patients.

      Besides, thrombin-based hemostatic agents, Floseal®(Baxter, Deerfield, Illinois), have been
      widely used in surgical procedure. Some recent studies demonstrated that topical use of
      Floseal® in primary TKA can reduce hemoglobin decline and calculated total blood loss after
      TKA. But other studies showed Floseal® does not reduce blood loss in TKA procedures.

      We believe the topical use of hemostatic agent in patients with high risk of thromboembolism
      can avoid its systematic effect and decrease its potential perioperative risk of
      thromboembolic complications (arterial thrombosis, myocardial infarction and pulmonary
      embolism). Recently, there were some reports demonstrating the cost-effectiveness of topical
      application of TXA in TKA patients. The blood saving effect of topical application of TXA in
      primary TKA was similar with systemic administration. The mean total blood loss of topical
      route of TXA inTKA patients was 940-1295 ml in different reports which was still high for
      patients with high thromboembolic risks. However, the efficacy and safety of topical use of
      TXA in TKA patients with history of thromboembolic disease is still unclear. A more effective
      regimen for bleeding prophylaxis afer primary TKA is necessary.

      We believe that combined topical applications of two hemostatic agents of different
      mechanisms can bring a synergistic effect in blood saving and does not increase the risk of
      thromboembolic disease after TKA.

      Our purpose of this study therefore is to conduct a prospective randomized controlled trial
      to investigate the blood-conservation effect of combined topical application of these two
      hemostatic agents in different time during surgery and the safety compared with single
      topical application of TKA in a primary TKA procedure.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 12, 2017</start_date>
  <completion_date type="Anticipated">October 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total blood loss after operation</measure>
    <time_frame>From the operation to the postoperative day 3 or 4</time_frame>
    <description>Total blood loss was calculated according to Nadler et al., which used maximum postoperative reduction of the Hb level adjust for weight and height of the patient. The formula is as follows, Total blood loss = (Total blood volume x [change in Hb level / preoperative Hb level])x1000+volume transfused</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood transfusion rate</measure>
    <time_frame>From the operation to the postoperative day 3 or 4</time_frame>
    <description>We will record the event of blood transfusion, and calculate the incidence of transfusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of thrombosis events</measure>
    <time_frame>within 30 days of the operation</time_frame>
    <description>The composite of any venous thromoembolism events, ischemic heart attacks, cerebrovascular accidents</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Combined topical TXA and Floseal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Floseal® was applied on potential bleeding sites before prosthesis implantation, and intraarticular application of topical tranexamic acid after capsule closure Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical TXA alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intraarticular application of topical tranexamic acid after capsule closure Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical tranexamic acid</intervention_name>
    <description>Intraarticular application of tranexamic acid 3g in 60 ml normal saline into knee joint after closure of the joint capsule</description>
    <arm_group_label>Combined topical TXA and Floseal</arm_group_label>
    <arm_group_label>Topical TXA alone</arm_group_label>
    <other_name>Topical transamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Floseal®</intervention_name>
    <description>Floseal® (Hemostatic matrix, 10ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 10 mL vial containing the active product (Floseal®) was used. The HM remained in place for 3 minutes and was then gently rinsed from the knee as recommended by the manufacturer (Baxter)</description>
    <arm_group_label>Combined topical TXA and Floseal</arm_group_label>
    <other_name>Thrombin-gelatin matrix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rivaroxaban (10mg)</intervention_name>
    <description>Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14.</description>
    <arm_group_label>Combined topical TXA and Floseal</arm_group_label>
    <arm_group_label>Topical TXA alone</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who have advanced knee osteoarthritis are scheduled to undergo primary,
             unilateral elective total knee replacement surgery

          2. Age &gt; 50 years and &lt; 90 years

          3. Failure of medical treatment or rehabilitation.

          4. Hemoglobin &gt; 11g/dl,

          5. No use of non-steroid anti-inflammatory agent one week before operation

        Exclusion Criteria:

          1. Preoperative Hemoglobin ≦11 g/dl

          2. History of infection or intraarticular fracture of the affective knee

          3. Renal function deficiency (GFR &lt;30 ml/min/1.73m2)which is relative contraindicated for
             chemical venous thromboembolism

          4. Elevated liver enzyme (AST/ALT level are more than twice normal range) , history of
             liver cirrhosis, impaired liver function(elevated total bilirubin level) and
             coagulopathy (including long-term use anticoagulant)

          5. History of deep vein thrombosis, ischemic heart disease or stroke

          6. Contraindications of tranexamic acid, floseal, or rivaroxaban

          7. Allergy to tranexamic acid, floseal, rivaroxaban, or the excipients

          8. History of heparin-induced thrombocytopenia (HIT)

          9. Coagulopathy or bleeding tendency caused by organ dysfunction, such as cirrhosis, bone
             marrow suppression etc.

         10. Patient who have active bleeding disorder, such as intracranial hemorrhage, upper GI
             bleeding, hematuria.

         11. Patients with known allergies to materials of bovine origin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun-Wen Wang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun-Wen Wang, MD</last_name>
    <phone>886-7-7317123</phone>
    <email>wangjw@adm.cgmh.org.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jun-Wen Wang, MD</last_name>
      <phone>886-7-7317123</phone>
      <email>wangjw@adm.cgmh.org.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Bong MR, Patel V, Chang E, Issack PS, Hebert R, Di Cesare PE. Risks associated with blood transfusion after total knee arthroplasty. J Arthroplasty. 2004 Apr;19(3):281-7.</citation>
    <PMID>15067638</PMID>
  </reference>
  <reference>
    <citation>Bierbaum BE, Callaghan JJ, Galante JO, Rubash HE, Tooms RE, Welch RB. An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am. 1999 Jan;81(1):2-10.</citation>
    <PMID>9973048</PMID>
  </reference>
  <reference>
    <citation>Goodnough LT, Verbrugge D, Marcus RE. The relationship between hematocrit, blood lost, and blood transfused in total knee replacement. Implications for postoperative blood salvage and reinfusion. Am J Knee Surg. 1995 Summer;8(3):83-7.</citation>
    <PMID>7552610</PMID>
  </reference>
  <reference>
    <citation>Tanaka N, Sakahashi H, Sato E, Hirose K, Ishima T, Ishii S. Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee. J Bone Joint Surg Br. 2001 Jul;83(5):702-5.</citation>
    <PMID>11476309</PMID>
  </reference>
  <reference>
    <citation>Alvarez JC, Santiveri FX, Ramos I, Vela E, Puig L, Escolano F. Tranexamic acid reduces blood transfusion in total knee arthroplasty even when a blood conservation program is applied. Transfusion. 2008 Mar;48(3):519-25. Epub 2007 Dec 7.</citation>
    <PMID>18067499</PMID>
  </reference>
  <reference>
    <citation>Petäjä J, Myllynen P, Myllylä G, Vahtera E. Fibrinolysis after application of a pneumatic tourniquet. Acta Chir Scand. 1987 Nov-Dec;153(11-12):647-51.</citation>
    <PMID>3124428</PMID>
  </reference>
  <reference>
    <citation>Kambayashi J, Sakon M, Yokota M, Shiba E, Kawasaki T, Mori T. Activation of coagulation and fibrinolysis during surgery, analyzed by molecular markers. Thromb Res. 1990 Oct 15;60(2):157-67.</citation>
    <PMID>2149215</PMID>
  </reference>
  <reference>
    <citation>Hiippala S, Strid L, Wennerstrand M, Arvela V, Mäntylä S, Ylinen J, Niemelä H. Tranexamic acid (Cyklokapron) reduces perioperative blood loss associated with total knee arthroplasty. Br J Anaesth. 1995 May;74(5):534-7.</citation>
    <PMID>7772427</PMID>
  </reference>
  <reference>
    <citation>Benoni G, Fredin H. Fibrinolytic inhibition with tranexamic acid reduces blood loss and blood transfusion after knee arthroplasty: a prospective, randomised, double-blind study of 86 patients. J Bone Joint Surg Br. 1996 May;78(3):434-40.</citation>
    <PMID>8636182</PMID>
  </reference>
  <reference>
    <citation>Ido K, Neo M, Asada Y, Kondo K, Morita T, Sakamoto T, Hayashi R, Kuriyama S. Reduction of blood loss using tranexamic acid in total knee and hip arthroplasties. Arch Orthop Trauma Surg. 2000;120(9):518-20.</citation>
    <PMID>11011672</PMID>
  </reference>
  <reference>
    <citation>Lin PC, Hsu CH, Chen WS, Wang JW. Does tranexamic acid save blood in minimally invasive total knee arthroplasty? Clin Orthop Relat Res. 2011 Jul;469(7):1995-2002. doi: 10.1007/s11999-011-1789-y. Epub 2011 Feb 1.</citation>
    <PMID>21286886</PMID>
  </reference>
  <reference>
    <citation>Graham ID, Alvarez G, Tetroe J, McAuley L, Laupacis A. Factors influencing the adoption of blood alternatives to minimize allogeneic transfusion: the perspective of eight Ontario hospitals. Can J Surg. 2002 Apr;45(2):132-40.</citation>
    <PMID>11939657</PMID>
  </reference>
  <reference>
    <citation>Nishihara S, Hamada M. Does tranexamic acid alter the risk of thromboembolism after total hip arthroplasty in the absence of routine chemical thromboprophylaxis? Bone Joint J. 2015 Apr;97-B(4):458-62. doi: 10.1302/0301-620X.97B4.34656.</citation>
    <PMID>25820882</PMID>
  </reference>
  <reference>
    <citation>Xie J, Ma J, Kang P, Zhou Z, Shen B, Yang J, Pei F. Does tranexamic acid alter the risk of thromboembolism following primary total knee arthroplasty with sequential earlier anticoagulation? A large, single center, prospective cohort study of consecutive cases. Thromb Res. 2015 Aug;136(2):234-8. doi: 10.1016/j.thromres.2015.05.014. Epub 2015 May 21.</citation>
    <PMID>26026635</PMID>
  </reference>
  <reference>
    <citation>Wong J, Abrishami A, El Beheiry H, Mahomed NN, Roderick Davey J, Gandhi R, Syed KA, Muhammad Ovais Hasan S, De Silva Y, Chung F. Topical application of tranexamic acid reduces postoperative blood loss in total knee arthroplasty: a randomized, controlled trial. J Bone Joint Surg Am. 2010 Nov 3;92(15):2503-13. doi: 10.2106/JBJS.I.01518.</citation>
    <PMID>21048170</PMID>
  </reference>
  <reference>
    <citation>Wind TC, Barfield WR, Moskal JT. The effect of tranexamic acid on blood loss and transfusion rate in primary total knee arthroplasty. J Arthroplasty. 2013 Aug;28(7):1080-3. doi: 10.1016/j.arth.2012.11.016. Epub 2013 Mar 28.</citation>
    <PMID>23541868</PMID>
  </reference>
  <reference>
    <citation>Chimento GF, Huff T, Ochsner JL Jr, Meyer M, Brandner L, Babin S. An evaluation of the use of topical tranexamic acid in total knee arthroplasty. J Arthroplasty. 2013 Sep;28(8 Suppl):74-7. doi: 10.1016/j.arth.2013.06.037.</citation>
    <PMID>24034510</PMID>
  </reference>
  <reference>
    <citation>Konig G, Hamlin BR, Waters JH. Topical tranexamic acid reduces blood loss and transfusion rates in total hip and total knee arthroplasty. J Arthroplasty. 2013 Oct;28(9):1473-6. doi: 10.1016/j.arth.2013.06.011. Epub 2013 Jul 23.</citation>
    <PMID>23886406</PMID>
  </reference>
  <reference>
    <citation>Georgiadis AG, Muh SJ, Silverton CD, Weir RM, Laker MW. A prospective double-blind placebo controlled trial of topical tranexamic acid in total knee arthroplasty. J Arthroplasty. 2013 Sep;28(8 Suppl):78-82. doi: 10.1016/j.arth.2013.03.038. Epub 2013 Jul 29.</citation>
    <PMID>23906869</PMID>
  </reference>
  <reference>
    <citation>Gazzeri R, Galarza M, Alfier A. Safety biocompatibility of gelatin hemostatic matrix (Floseal and Surgiflo) in neurosurgical procedures. Surg Technol Int. 2012 Dec;22:49-54.</citation>
    <PMID>22915500</PMID>
  </reference>
  <reference>
    <citation>Clapp M, Huang JC. Use of FloSeal Sealant in the Surgical Management of Tubal Ectopic Pregnancy. Case Rep Obstet Gynecol. 2013;2013:906825. doi: 10.1155/2013/906825. Epub 2013 May 29.</citation>
    <PMID>23819082</PMID>
  </reference>
  <reference>
    <citation>Testini M, Marzaioli R, Lissidini G, Lippolis A, Logoluso F, Gurrado A, Lardo D, Poli E, Piccinni G. The effectiveness of FloSeal matrix hemostatic agent in thyroid surgery: a prospective, randomized, control study. Langenbecks Arch Surg. 2009 Sep;394(5):837-42. doi: 10.1007/s00423-009-0497-5. Epub 2009 May 7.</citation>
    <PMID>19421770</PMID>
  </reference>
  <reference>
    <citation>Di Francesco A, Flamini S, Fiori F, Mastri F. Hemostatic matrix effects on blood loss after total knee arthroplasty: A randomized controlled trial. Indian J Orthop. 2013 Sep;47(5):474-81. doi: 10.4103/0019-5413.118203.</citation>
    <PMID>24133307</PMID>
  </reference>
  <reference>
    <citation>Suarez JC, Slotkin EM, Alvarez AM, Szubski CR, Barsoum WK, Patel PD. Prospective, randomized trial to evaluate efficacy of a thrombin-based hemostatic agent in total knee arthroplasty. J Arthroplasty. 2014 Oct;29(10):1950-5. doi: 10.1016/j.arth.2014.05.025. Epub 2014 Jun 5.</citation>
    <PMID>25015756</PMID>
  </reference>
  <reference>
    <citation>Kim HJ, Fraser MR, Kahn B, Lyman S, Figgie MP. The efficacy of a thrombin-based hemostatic agent in unilateral total knee arthroplasty: a randomized controlled trial. J Bone Joint Surg Am. 2012 Jul 3;94(13):1160-5. doi: 10.2106/JBJS.K.00531.</citation>
    <PMID>22623075</PMID>
  </reference>
  <reference>
    <citation>Helito CP, Gobbi RG, Castrillon LM, Hinkel BB, Pécora JR, Camanho GL. Comparison of Floseal(r) and electrocautery in hemostasis after total knee arthroplasty. Acta Ortop Bras. 2013;21(6):320-2. doi: 10.1590/S1413-78522013000600004.</citation>
    <PMID>24453689</PMID>
  </reference>
  <reference>
    <citation>Comadoll JL, Comadoll S, Hutchcraft A, Krishnan S, Farrell K, Kreuwel HT, Bechter M. Comparison of hemostatic matrix and standard hemostasis in patients undergoing primary TKA. Orthopedics. 2012 Jun;35(6):e785-93. doi: 10.3928/01477447-20120525-14.</citation>
    <PMID>22691647</PMID>
  </reference>
  <reference>
    <citation>Bae KC, Cho CH, Lee KJ, Son ES, Lee SW, Lee SJ, Lim KH. Efficacy of intra-articular injection of thrombin-based hemostatic agent in the control of bleeding after primary total knee arthroplasty. Knee Surg Relat Res. 2014 Dec;26(4):236-40. doi: 10.5792/ksrr.2014.26.4.236. Epub 2014 Dec 2.</citation>
    <PMID>25505706</PMID>
  </reference>
  <reference>
    <citation>Schwab PE, Thienpont E. Use of a haemostatic matrix does not reduce blood loss in minimally invasive total knee arthroplasty. Blood Transfus. 2015 Jul;13(3):435-41. doi: 10.2450/2015.0199-14. Epub 2015 Jan 26.</citation>
    <PMID>25761324</PMID>
  </reference>
  <reference>
    <citation>Schwab PE, Thienpont E. Use of a haemostatic matrix (Floseal®) does not reduce blood loss in minimally invasive total knee arthroplasty performed under continued aspirin. Blood Transfus. 2016 Mar;14(2):134-9. doi: 10.2450/2015.0023-15. Epub 2015 May 29.</citation>
    <PMID>26057492</PMID>
  </reference>
  <reference>
    <citation>Lin SY, Chen CH, Fu YC, Huang PJ, Chang JK, Huang HT. The efficacy of combined use of intraarticular and intravenous tranexamic acid on reducing blood loss and transfusion rate in total knee arthroplasty. J Arthroplasty. 2015 May;30(5):776-80. doi: 10.1016/j.arth.2014.12.001. Epub 2014 Dec 5.</citation>
    <PMID>25534864</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2017</study_first_submitted>
  <study_first_submitted_qc>October 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2017</study_first_posted>
  <last_update_submitted>October 30, 2017</last_update_submitted>
  <last_update_submitted_qc>October 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chang Gung Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Wang Jun-Wen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Thrombin-gelatin matrix</keyword>
  <keyword>Floseal</keyword>
  <keyword>Tranexamic Acid</keyword>
  <keyword>Total Knee Arthroplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
    <mesh_term>Thrombin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

